Terms: = Prostate cancer AND RUNX1, PEBP2A2, 861, ENSG00000159216, Q01196, AML1, CBFA2, AMLCR1 AND Treatment
34 results:
1. A Literature Review of Racial Disparities in prostate cancer Research.
Vermeille M; Koster KL; Benzaquen D; Champion A; Taussky D; Kaulanjan K; Früh M
Curr Oncol; 2023 Nov; 30(11):9886-9894. PubMed ID: 37999138
[TBL] [Abstract] [Full Text] [Related]
2. 5-alpha reductase inhibitors (5-ARi) with or without alpha-blockers (α-B) for Benign Prostatic Hyperplasia do NOT lower the risk of incident Bladder cancer: United States insurance claims data.
Del Giudice F; Belladelli F; Glover F; Basran S; Li S; Mulloy E; Pradere B; Soria F; Krajewski W; Nair R; Muncey W; Seranio N; Eisenberg ML
World J Urol; 2023 Oct; 41(10):2783-2791. PubMed ID: 37548746
[TBL] [Abstract] [Full Text] [Related]
3. Holothurin A Inhibits runx1-Enhanced EMT in Metastasis prostate cancer via the Akt/JNK and P38 MAPK Signaling Pathway.
Janta S; Pranweerapaiboon K; Vivithanaporn P; Plubrukarn A; Chairoungdua A; Prasertsuksri P; Apisawetakan S; Chaithirayanon K
Mar Drugs; 2023 Jun; 21(6):. PubMed ID: 37367670
[TBL] [Abstract] [Full Text] [Related]
4. Follow-up strategy and survival for five common cancers: A meta-analysis.
Galjart B; Höppener DJ; Aerts JGJV; Bangma CH; Verhoef C; Grünhagen DJ
Eur J Cancer; 2022 Oct; 174():185-199. PubMed ID: 36037595
[TBL] [Abstract] [Full Text] [Related]
5. Autocrine Canonical Wnt Signaling Primes Noncanonical Signaling through ROR1 in Metastatic Castration-Resistant prostate cancer.
Ma F; Arai S; Wang K; Calagua C; Yuan AR; Poluben L; Gu Z; Russo JW; Einstein DJ; Ye H; He MX; Liu Y; Van Allen E; Sowalsky AG; Bhasin MK; Yuan X; Balk SP
Cancer Res; 2022 Apr; 82(8):1518-1533. PubMed ID: 35131873
[TBL] [Abstract] [Full Text] [Related]
6. Computer-aided segmentation on MRI for prostate radiotherapy, Part I: Quantifying human interobserver variability of the prostate and organs at risk and its impact on radiation dosimetry.
Sanders JW; Mok H; Hanania AN; Venkatesan AM; Tang C; Bruno TL; Thames HD; Kudchadker RJ; Frank SJ
Radiother Oncol; 2022 Apr; 169():124-131. PubMed ID: 34921895
[TBL] [Abstract] [Full Text] [Related]
7. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for prostate cancer treatment.
Wallach JD; Deng Y; McCoy RG; Dhruva SS; Herrin J; Berkowitz A; Polley EC; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Shah ND; Ross JS; Lyon TD
JAMA Netw Open; 2021 Oct; 4(10):e2130587. PubMed ID: 34677594
[TBL] [Abstract] [Full Text] [Related]
8. The impact of the COVID-19 pandemic on the short-term survival of patients with cancer in Northern Portugal.
Morais S; Antunes L; Rodrigues J; Fontes F; Bento MJ; Lunet N
Int J Cancer; 2021 Jul; 149(2):287-296. PubMed ID: 33634852
[TBL] [Abstract] [Full Text] [Related]
9. Urology Workforce Changes and Implications for prostate cancer Care Among Medicare Enrollees.
Marchetti KA; Oerline M; Hollenbeck BK; Kaufman SR; Skolarus TA; Shahinian VB; Caram MEV; Modi PK
Urology; 2021 Sep; 155():77-82. PubMed ID: 33610652
[TBL] [Abstract] [Full Text] [Related]
10. Assessment of Secondary Sarcomas Among Patients With cancer of the Abdomen or Pelvis Who Received Combinations of Surgery, Radiation, and Chemotherapy vs Surgery Alone.
Hird AE; Magee DE; Matta R; Saskin R; Dvorani E; Kulkarni GS; Kodama R; Herschorn S; Narod SA; Nam RK
JAMA Netw Open; 2020 Oct; 3(10):e2013929. PubMed ID: 33006617
[TBL] [Abstract] [Full Text] [Related]
11. Hypofractionated radiotherapy versus conventional radiotherapy in patients with intermediate- to high-risk localized prostate cancer: a meta-analysis of randomized controlled trials.
Guo W; Sun YC; Bi JQ; He XY; Xiao L
BMC Cancer; 2019 Nov; 19(1):1063. PubMed ID: 31703647
[TBL] [Abstract] [Full Text] [Related]
12. cancer treatment and survivorship statistics, 2019.
Miller KD; Nogueira L; Mariotto AB; Rowland JH; Yabroff KR; Alfano CM; Jemal A; Kramer JL; Siegel RL
CA Cancer J Clin; 2019 Sep; 69(5):363-385. PubMed ID: 31184787
[TBL] [Abstract] [Full Text] [Related]
13. Evaluation of the contribution of demographics, access to health care, treatment, and tumor characteristics to racial differences in survival of advanced prostate cancer.
Krimphove MJ; Cole AP; Fletcher SA; Harmouch SS; Berg S; Lipsitz SR; Sun M; Nabi J; Nguyen PL; Hu JC; Kibel AS; Choueiri TK; Kluth LA; Trinh QD
Prostate Cancer Prostatic Dis; 2019 Mar; 22(1):125-136. PubMed ID: 30171227
[TBL] [Abstract] [Full Text] [Related]
14. Taxane chemotherapy vs antiandrogen agents as first-line therapy for metastatic castration-resistant prostate cancer.
Sonpavde G; Huang A; Wang L; Baser O; Miao R
BJU Int; 2018 Jun; 121(6):871-879. PubMed ID: 29388324
[TBL] [Abstract] [Full Text] [Related]
15. miR-141 inhibits prostatic cancer cell proliferation and migration, and induces cell apoptosis via targeting of runx1.
Xu S; Ge J; Zhang Z; Zhou W
Oncol Rep; 2018 Mar; 39(3):1454-1460. PubMed ID: 29328406
[TBL] [Abstract] [Full Text] [Related]
16. Initial computed tomography imaging details during first-line systemic therapy is of significant prognostic value in patients with naïve, unresectable metastatic renal cell carcinoma.
Kim SH; Park WS; Kim SH; Seo HK; Joung JY; Lee KH; Chung J
PLoS One; 2017; 12(5):e0177975. PubMed ID: 28562690
[TBL] [Abstract] [Full Text] [Related]
17. Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease.
Blackledge MD; Tunariu N; Orton MR; Padhani AR; Collins DJ; Leach MO; Koh DM
PLoS One; 2016; 11(4):e0153840. PubMed ID: 27123931
[TBL] [Abstract] [Full Text] [Related]
18. Comparison of Perioperative and Early Oncologic Outcomes between Open and Robotic Assisted Laparoscopic prostatectomy in a Contemporary Population Based Cohort.
Pearce SM; Pariser JJ; Karrison T; Patel SG; Eggener SE
J Urol; 2016 Jul; 196(1):76-81. PubMed ID: 26860793
[TBL] [Abstract] [Full Text] [Related]
19. Lack of Cumulative Toxicity Associated With Cabazitaxel Use in prostate cancer.
Di Lorenzo G; Bracarda S; Gasparro D; Gernone A; Messina C; Zagonel V; Puglia L; Bosso D; Dondi D; Sonpavde G; Lucarelli G; De Placido S; Buonerba C
Medicine (Baltimore); 2016 Jan; 95(2):e2299. PubMed ID: 26765406
[TBL] [Abstract] [Full Text] [Related]
20. BPH: a tell-tale sign of prostate cancer? Results from the prostate cancer and Environment Study (PROtEuS).
Boehm K; Valdivieso R; Meskawi M; Larcher A; Sun M; Sosa J; Blanc-Lapierre A; Weiss D; Graefen M; Saad F; Parent MÉ; Karakiewicz PI
World J Urol; 2015 Dec; 33(12):2063-9. PubMed ID: 25824539
[TBL] [Abstract] [Full Text] [Related]
[Next]
